All Outputs (41)

PRO-C3 is a predictor of clinical outcomes in distinct cohorts of patients with advanced liver disease (2023)
Journal Article
Nielsen, M. J., Dolman, G. E., Harris, R., Frederiksen, P., Chalmers, J., Grove, J. I., …Guha, I. N. (2023). PRO-C3 is a predictor of clinical outcomes in distinct cohorts of patients with advanced liver disease. JHEP Reports, 5(6), Article 100743. https://doi.org/10.1016/j.jhepr.2023.100743

Background & Aims: Fibroblast activity is a key feature of fibrosis progression and organ function loss, leading to liver-related complications and mortality. The fibrogenesis marker, PRO-C3, has been shown to have prognostic significance in relation... Read More about PRO-C3 is a predictor of clinical outcomes in distinct cohorts of patients with advanced liver disease.

Delivery of biannual ultrasound surveillance for individuals with cirrhosis and cured hepatitis C in the UK (2023)
Journal Article
Hamill, V., Gelson, W., MacDonald, D., Richardson, P., Ryder, S. D., Aldersley, M., …Innes, H. (2023). Delivery of biannual ultrasound surveillance for individuals with cirrhosis and cured hepatitis C in the UK. Liver International, 43(4), 917-927. https://doi.org/10.1111/liv.15528

Background: Previous studies show the uptake of biannual ultrasound (US) surveillance in patients with cirrhosis is suboptimal. Here, our goal was to understand in broader terms how surveillance is being delivered to cirrhosis patients with cured hep... Read More about Delivery of biannual ultrasound surveillance for individuals with cirrhosis and cured hepatitis C in the UK.

Comparing magnetic resonance liver fat fraction measurements with histology in fibrosis: the difference between proton density fat fraction and tissue mass fat fraction (2022)
Journal Article
Bawden, S. J., Hoad, C., Kaye, P., Stephenson, M., Dolman, G., James, M. W., …Aithal, G. P. (2023). Comparing magnetic resonance liver fat fraction measurements with histology in fibrosis: the difference between proton density fat fraction and tissue mass fat fraction. Magnetic Resonance Materials in Physics, Biology and Medicine, 36(4), 553-563. https://doi.org/10.1007/s10334-022-01052-0

Objective: Magnetic resonance spectroscopy (MRS) provides a powerful method of measuring fat fraction. However, previous studies have shown that MRS results give lower values compared with visual estimates from biopsies in fibrotic livers. This study... Read More about Comparing magnetic resonance liver fat fraction measurements with histology in fibrosis: the difference between proton density fat fraction and tissue mass fat fraction.

Low Accuracy of FIB-4 and NAFLD Fibrosis Scores for Screening for Liver Fibrosis in the Population (2022)
Journal Article
Graupera, I., Thiele, M., Serra-Burriel, M., Caballeria, L., Roulot, D., Wong, G. L., …Krag, A. (2022). Low Accuracy of FIB-4 and NAFLD Fibrosis Scores for Screening for Liver Fibrosis in the Population. Clinical Gastroenterology and Hepatology, 20(11), 2567-2576.e6. https://doi.org/10.1016/j.cgh.2021.12.034

Background & Aims Fibrosis-4 (FIB-4) and the nonalcoholic fatty liver disease fibrosis score (NFS) are the 2 most popular noninvasive blood-based serum tests proposed for widespread fibrosis screening. We therefore aimed to describe the accuracy o... Read More about Low Accuracy of FIB-4 and NAFLD Fibrosis Scores for Screening for Liver Fibrosis in the Population.

Variability of noninvasive MRI and biological markers in compensated cirrhosis: insights for assessing disease progression (2022)
Journal Article
Bradley, C. R., Cox, E. F., Palaniyappan, N., Aithal, G. P., Francis, S. T., & Guha, I. N. (2022). Variability of noninvasive MRI and biological markers in compensated cirrhosis: insights for assessing disease progression. European Radiology Experimental, 6(1), Article 52. https://doi.org/10.1186/s41747-022-00303-y

Abstract: Background: We annually monitored stable compensated cirrhosis (CC) patients to evaluate serial variation in blood serum, liver stiffness, and multiparametric magnetic resonance imaging (mpMRI) measures to provide reference change values (R... Read More about Variability of noninvasive MRI and biological markers in compensated cirrhosis: insights for assessing disease progression.

Liver blood marker testing in UK primary care: a UK wide cohort study, 2004-2016 (2022)
Journal Article
Scutt, P., Ban, L., Card, T., Crooks, C. J., Guha, N., West, J., & Morling, J. R. (2022). Liver blood marker testing in UK primary care: a UK wide cohort study, 2004-2016. BMJ Open, 12(9), e058967. https://doi.org/10.1136/bmjopen-2021-058967

OBJECTIVE: We aimed to determine (1) the temporal trends of liver enzyme testing in UK general practice and (2) how these vary among different subgroups at risk of chronic liver disease (CLD). DESIGN: Retrospective cohort study. SETTING: UK primary c... Read More about Liver blood marker testing in UK primary care: a UK wide cohort study, 2004-2016.

Genetic variation in TERT modifies the risk of hepatocellular carcinoma in alcohol-related cirrhosis: Results from a genome-wide case-control study (2022)
Journal Article
Buch, S., Innes, H., Lutz, P. L., Nischalke, H. D., Marquardt, J. U., Fischer, J., …Stickel, F. (2022). Genetic variation in TERT modifies the risk of hepatocellular carcinoma in alcohol-related cirrhosis: Results from a genome-wide case-control study. Gut, https://doi.org/10.1136/gutjnl-2022-327196

Objective: Hepatocellular carcinoma (HCC) often develops in patients with alcohol-related cirrhosis at an annual risk of up to 2.5%. Some host genetic risk factors have been identified but do not account for the majority of the variance in occurrence... Read More about Genetic variation in TERT modifies the risk of hepatocellular carcinoma in alcohol-related cirrhosis: Results from a genome-wide case-control study.

Performance of routine risk scores for predicting cirrhosis-related morbidity in the community (2022)
Journal Article
Innes, H., Morling, J. R., Buch, S., Hamill, V., Stickel, F., & Guha, I. N. (2022). Performance of routine risk scores for predicting cirrhosis-related morbidity in the community. Journal of Hepatology, 77(2), 365-376. https://doi.org/10.1016/j.jhep.2022.02.022

BACKGROUND & AIMS: Models predicting an individual’s ten-year risk of cirrhosis complications have not been developed for a community setting. Our objectives were to assess the performance of existing risk scores – both with and without genetic data... Read More about Performance of routine risk scores for predicting cirrhosis-related morbidity in the community.

Transient Elastography in Community Alcohol Services: Can It Detect Significant Liver Disease and Impact Drinking Behaviour? (2022)
Journal Article
Subhani, M., Harman, D. J., Scott, R. A., Bennett, L., Wilkes, E. A., James, M. W., …Guha, I. N. (2022). Transient Elastography in Community Alcohol Services: Can It Detect Significant Liver Disease and Impact Drinking Behaviour?. Biomedicines, 10(2), Article 477. https://doi.org/10.3390/biomedicines10020477

Introduction: Alcohol is the leading cause of cirrhosis in Western populations. The early identification of high-risk drinkers followed by intervention is an effective way to reduce harm. We aim to assess the feasibility of integrating transient elas... Read More about Transient Elastography in Community Alcohol Services: Can It Detect Significant Liver Disease and Impact Drinking Behaviour?.

Health Technology Adoption in Liver Disease: Innovative Use of Data Science Solutions for Early Disease Detection (2022)
Journal Article
Bennett, L., Purssell, H., Street, O., Piper Hanley, K., Morling, J. R., Hanley, N. A., …ID-LIVER Consortium. (2022). Health Technology Adoption in Liver Disease: Innovative Use of Data Science Solutions for Early Disease Detection. Frontiers in Digital Health, 4, Article 737729. https://doi.org/10.3389/fdgth.2022.737729

Chronic liver disease (CLD) is an ignored epidemic. Premature mortality is considerable and in the United Kingdom (UK) liver disease is in the top three for inequitable healthcare alongside heart and respiratory disease. Fifty percentage of patients... Read More about Health Technology Adoption in Liver Disease: Innovative Use of Data Science Solutions for Early Disease Detection.

The rs429358 Locus in Apolipoprotein E Is Associated With Hepatocellular Carcinoma in Patients With Cirrhosis (2021)
Journal Article
Innes, H., Nischalke, H. D., Guha, I. N., Weiss, K. H., Irving, W., Gotthardt, D., …Buch, S. (2022). The rs429358 Locus in Apolipoprotein E Is Associated With Hepatocellular Carcinoma in Patients With Cirrhosis. Hepatology Communications, 6(5), 1213-1226. https://doi.org/10.1002/hep4.1886

The host genetic background for hepatocellular carcinoma (HCC) is incompletely understood. We aimed to determine if four germline genetic polymorphisms, rs429358 in apolipoprotein E (APOE), rs2642438 in mitochondrial amidoxime reducing component 1 (M... Read More about The rs429358 Locus in Apolipoprotein E Is Associated With Hepatocellular Carcinoma in Patients With Cirrhosis.

Population screening for liver fibrosis: Toward early diagnosis and intervention for chronic liver diseases (2021)
Journal Article
Ginès, P., Castera, L., Lammert, F., Graupera, I., Serra‐Burriel, M., Allen, A. M., …Krag, A. (2022). Population screening for liver fibrosis: Toward early diagnosis and intervention for chronic liver diseases. Hepatology, 75(1), 219-228. https://doi.org/10.1002/hep.32163

Cirrhosis, highly prevalent worldwide, develops after years of hepatic inflammation triggering progressive fibrosis. Currently, the main etiologies of cirrhosis are non-alcoholic fatty liver disease and alcohol-related liver disease, although chronic... Read More about Population screening for liver fibrosis: Toward early diagnosis and intervention for chronic liver diseases.

Performance of models to predict hepatocellular carcinoma risk among UK patients with cirrhosis and cured HCV infection (2021)
Journal Article
Innes, H., Jepsen, P., McDonald, S., Dillon, J., Hamill, V., Yeung, A., …Guha, I. N. (2021). Performance of models to predict hepatocellular carcinoma risk among UK patients with cirrhosis and cured HCV infection. JHEP Reports, 3(6), Article 100384. https://doi.org/10.1016/j.jhepr.2021.100384

Background & Aims: Hepatocellular carcinoma (HCC) prediction models can inform clinical decisions about HCC screening provided their predictions are robust. We conducted an external validation of 6 HCC prediction models for UK patients with cirrhosis... Read More about Performance of models to predict hepatocellular carcinoma risk among UK patients with cirrhosis and cured HCV infection.

Characterizing the risk interplay between alcohol intake and body mass index on cirrhosis morbidity (2021)
Journal Article
Innes, H., Crooks, C. J., Aspinall, E., Card, T. R., Hamill, V., Dillon, J., …Morling, J. R. (2022). Characterizing the risk interplay between alcohol intake and body mass index on cirrhosis morbidity. Hepatology, 75(2), 369-378. https://doi.org/10.1002/hep.32123

Background and Aims: It is thought that alcohol intake and body mass index (BMI) interact supra-additively to modulate the risk of cirrhosis, but evidence for this phenomenon is limited. We investigated the interrelationship between alcohol and BMI o... Read More about Characterizing the risk interplay between alcohol intake and body mass index on cirrhosis morbidity.

Reliable computational quantification of liver fibrosis is compromised by inherent staining variation (2021)
Journal Article
Astbury, S., Grove, J. I., Dorward, D. A., Guha, I. N., Fallowfield, J. A., & Kendall, T. J. (2021). Reliable computational quantification of liver fibrosis is compromised by inherent staining variation. Journal of Pathology: Clinical Research, 7(5), 471-481. https://doi.org/10.1002/cjp2.227

Biopsy remains the gold standard measure for staging liver disease, both to inform prognosis and to assess the response to a given treatment. Semiquantitative scores such as the Ishak fibrosis score are used for evaluation. These scores are utilised... Read More about Reliable computational quantification of liver fibrosis is compromised by inherent staining variation.

Addition of hyaluronic acid to the FIB-4 liver fibrosis score improves prediction of incident cirrhosis and hepatocellular carcinoma in Type 2 diabetes: The Edinburgh Type 2 Diabetes Study (2021)
Journal Article
Grecian, S. M., McLachlan, S., Fallowfield, J. A., Hayes, P. C., Guha, I. N., Morling, J. R., …Strachan, M. W. (2021). Addition of hyaluronic acid to the FIB-4 liver fibrosis score improves prediction of incident cirrhosis and hepatocellular carcinoma in Type 2 diabetes: The Edinburgh Type 2 Diabetes Study. Obesity Science and Practice, 7(5), 497-508. https://doi.org/10.1002/osp4.484

Background: Type 2 diabetes is associated with increased risk of progression to cirrhosis and hepatocellular carcinoma (HCC) in people with chronic liver diseases, particularly non-alcoholic fatty liver disease (NAFLD). However, the absolute risk of... Read More about Addition of hyaluronic acid to the FIB-4 liver fibrosis score improves prediction of incident cirrhosis and hepatocellular carcinoma in Type 2 diabetes: The Edinburgh Type 2 Diabetes Study.

In severe alcoholic hepatitis, serum cytokeratin-18 fragments are diagnostic, prognostic and theragnostic biomarkers (2020)
Journal Article
Atkinson, S. R., Grove, J. I., Liebig, S., Astbury, S., Vergis, N., Goldin, R., …Aithal, G. P. (2020). In severe alcoholic hepatitis, serum cytokeratin-18 fragments are diagnostic, prognostic and theragnostic biomarkers. American Journal of Gastroenterology, 115(11), 1857-1868. https://doi.org/10.14309/ajg.0000000000000912

INTRODUCTION: Up to 40% of patients with severe alcoholic hepatitis (AH) die within 6 months of presentation, making prompt diagnosis and appropriate treatment essential. We determined the associations between serum keratin-18 (K18) and histologi... Read More about In severe alcoholic hepatitis, serum cytokeratin-18 fragments are diagnostic, prognostic and theragnostic biomarkers.

Health related quality of life in individuals at high risk of chronic liver disease: Impact of a community diagnostic pathway (2020)
Journal Article
Tildesley, Z., Chalmers, J., Harris, R., West, J., Guha, I. N., & Morling, J. R. (2020). Health related quality of life in individuals at high risk of chronic liver disease: Impact of a community diagnostic pathway. Public Health In Practice, 1, https://doi.org/10.1016/j.puhip.2020.100033

Objectives: There is a lack of understanding of health related quality of life (HRQoL) in chronic liver disease (CLD). With the rising prevalence of alcohol and obesity driven CLD, and the increasing ability to screen for fibrosis, it is important to... Read More about Health related quality of life in individuals at high risk of chronic liver disease: Impact of a community diagnostic pathway.

aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis (2020)
Journal Article
Fan, R., Papatheodoridis, G., Sun, J., Innes, H., Toyoda, H., Xie, Q., …Hou, J. (2020). aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis. Journal of Hepatology, 73(6), 1368-1378. https://doi.org/10.1016/j.jhep.2020.07.025

© 2020 European Association for the Study of the Liver Background & Aims: Hepatocellular carcinoma (HCC) is the leading cause of death in patients with chronic hepatitis. In this international collaboration, we sought to develop a global universal HC... Read More about aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis.

Non-invasive risk scores do not reliably identify future cirrhosis or hepatocellular carcinoma in Type 2 diabetes: The Edinburgh Type 2 Diabetes Study (2020)
Journal Article
Grecian, S. M., McLachlan, S., Fallowfield, J. A., Kearns, P. K., Hayes, P. C., Guha, N. I., …Strachan, M. W. (2020). Non-invasive risk scores do not reliably identify future cirrhosis or hepatocellular carcinoma in Type 2 diabetes: The Edinburgh Type 2 Diabetes Study. Liver International, 40(9), 2252-2262. https://doi.org/10.1111/liv.14590

Background The incidence of cirrhosis and hepatocellular carcinoma (HCC) is increased in Type 2 diabetes, primarily secondary to non‐alcoholic fatty liver disease (NAFLD). European guidelines recommend screening for NAFLD in Type 2 diabetes. America... Read More about Non-invasive risk scores do not reliably identify future cirrhosis or hepatocellular carcinoma in Type 2 diabetes: The Edinburgh Type 2 Diabetes Study.